Literature DB >> 14671808

[Cardiovascular pharmacotherapy in the aged].

M Baumhäkel1, M Böhm.   

Abstract

Prevalence of cardiovascular diseases increases with advancing age. Moreover, these patients are getting older and older. Therefore, pharmacotherapy of the elderly becomes a major objective in clinical cardiology. Pharmacodynamic and pharmacokinetic changes in the elderly can interfere with a sufficient treatment of cardiovascular diseases and moreover, multiple drug usage is a considerable risk factor of possible drug-drug interactions. Furthermore, treatment of cardiovascular diseases as hypertension, heart failure or coronary heart disease in the elderly according to the international guidelines is often limited due to co-morbidities restricting usage of the appropriate medication. This review addresses both, the treatment of cardiovascular diseases in the elderly and the pharmacological characteristics of frequently used drugs.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14671808     DOI： 10.1007/s00108-003-0939-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  44 in total

1.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

2.  Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.

Authors:  Shelley R Salpeter; Thomas M Ormiston; Edwin E Salpeter
Journal:  Ann Intern Med       Date:  2002-11-05       Impact factor: 25.391

3.  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.

Authors:  F Zannad; F Alla; B Dousset; A Perez; B Pitt
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

Review 4.  [Digitalis therapy in the aged].

Authors:  E Erdmann
Journal:  Verh Dtsch Ges Inn Med       Date:  1990

5.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

Authors:  L Liu; J G Wang; L Gong; G Liu; J A Staessen
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

6.  Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study.

Authors:  D Franzen; A Metha; N Seifert; M Braun; H W Höpp
Journal:  Int J Impot Res       Date:  2001-12       Impact factor: 2.896

7.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

Review 8.  Considerations on current and future trials in hypertension.

Authors:  G Mancia; G Grassi
Journal:  Blood Press       Date:  1996-11       Impact factor: 2.835

9.  Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry).

Authors:  Giovanni Pulignano; Donatella Del Sindaco; Luigi Tavazzi; Donata Lucci; Marco Gorini; Francesco Leggio; Maurizio Porcu; Marino Scherillo; Cristina Opasich; Andrea Di Lenarda; Michele Senni; Aldo Pietro Maggioni
Journal:  Am Heart J       Date:  2002-01       Impact factor: 4.749

10.  Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).

Authors:  J Kjekshus; T R Pedersen
Journal:  Am J Cardiol       Date:  1995-09-28       Impact factor: 2.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.